Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

The Phillippines (1)

United Arab Emirates (1)


  • 12/12/2023
  • Press Release

STADA further improves Sustainability ranking again: rates among top 6% of pharma players globally

  • STADA further improves independent sustainability ranking; Sustainalytics ESG Risk Rating puts STADA among top 6% of pharma firms globally

  • Sustainalytics: “STADA Arzneimittel AG’s management of ESG material risk is strong”

  • STADA CEO Peter Goldschmidt: "STADA’s ongoing commitment to further driving sustainability across all our activities reflects the Group’s overarching purpose of Caring for People’s Health as a Trusted Partner"

Bad Vilbel –
12 December 2023 – STADA is among the most sustainable pharmaceutical companies globally, an independent assessment has confirmed. Assessing STADA for the first time as “low risk” in its Environmental, Social and Governance (ESG) Risk Ratings, independent agency Sustainalytics ranked STADA among the top 6% of all companies within its Pharmaceuticals sector comprising almost 900 companies appraised in terms of ESG risk.

“STADA Arzneimittel AG’s management of ESG material risk is strong,” Sustainalytics stated in improving STADA’s risk rating from 22.2, or “medium risk” in December 2022, to 18.4, or “low risk”, in December 2023[1]. This assessment is based on a comprehensive framework of more than 70 management indicators that are designed to provide an in-depth analysis of a company’s ESG strengths and weaknesses compared to its competitors and the overall industry performance.

This improved ranking places STADA 48th within the Pharmaceuticals cohort of 885 companies. Furthermore, STADA is ranked among the top quartile of the global universe of more than 15,000 organizations evaluated by Sustainalytics.

In particular, Sustainalytics assessed as “strong” STADA’s risk management in terms of: product governance; business ethics; corporate governance; emissions, effluent and waste; carbon from own operations; and bribery and corruption.

“It is gratifying that Sustainalytics has independently recognized the multiple initiatives STADA is implementing across diverse ESG topics,” commented STADA CEO Peter Goldschmidt. “Our ongoing commitment to further driving sustainability across all our activities reflects the Group’s overarching purpose of Caring for People’s Health as a Trusted Partner.”

STADA’s ESG initiatives and activities that contributed to the improved Sustainalytics rating, as well as progress on supporting United Nations Sustainable Development Goals to which the company is a signatory, are detailed in the Group’s Sustainability Report 2022[2].  

The Group continues to strive towards decarbonization, such as by using renewable energy. For example, greenhouse gas (GHC) emissions have reduced by 16.5% since 2020. As a supplier of around 1.2 billion medicines packs per year, STADA makes a significant contribution to affordable access to medicines. The Group is also committed to being a responsible and equitable employer, with a 53% share of women in management positions.

Further promoting diversity and uniqueness, as well as equal pay and fair working conditions, are among STADA’s priorities as the group continues its sustainability journey. The group continues to make progress with its access to medicines programme and to invest

in an environmentally-responsible supply chain, such as through a supply-chain hub currently being constructed in Turda, Romania, using ecologically-friendly technologies such as photovoltaic solar panels and low-energy lighting. Reducing ‘Scope 3’ carbon emissions remains a central focus of STADA’s sustainability initiatives.


[1] STADA Arzneimittel AG ESG Risk Rating (

[2] STADA Sustainability Report 2022 (Pdf)